FDA's Top Vaccine Officer Resigns Amid Debates

0:00On March 7th, here's the latest in global news. Dr. Vene Prasad, the Food and Drug Administration's top vaccine official, is stepping down from his role at the end of April. This march the second time, in less than a year, he's left the agency amid debates over vaccine approvals and treatments for rare diseases. FDA Commissioner Marty McCarrie shared the news with staff via email on Friday, noting Prasad will head back to his position at the University of California, San Francisco. Earlier this summer, Prasad faced backlash from biotech leaders, patient advocates, and others, leading to a short exit in July. He returned to the job less than two weeks later, with support from Health Secretary Robert F. Kennedy Jr. and McCarrie. His latest departure comes after months of clashes over how the FDA handles new vaccines and gene therapies. One of the executives, investors, and members of Congress have voiced strong frustration with Prasad's decisions. More than half a dozen companies developing therapies for tough diseases, got rejection

1:03notices, or calls for extra studies, which could add years and millions of dollars to their timelines. Critics say these moves slow down progress for patients. Take Moderna's new mRNA flu vaccine, for example. Our first block disk review, a rare step that drew public pushback from the company. A week later, the FDA flipped and agreed to consider it, but only after Moderna promised more data. Meanwhile, gene therapy firm Unicirae slammed the agency for requiring a new trial with fake surgeries on patients, calling it unethical and against. Past guidance. FDA officials fired back at a Thursday news briefing, labeling the company's original work a failure. Prasad, a longtime FDA skeptic from academia, started at the agency last May, pushing for quicker reviews alongside McCarrie. Yet, he's also added strict warnings and study demands, especially for COVID vaccines, a hot topic for Kennedy. As he exits, questions linger about the balance between speed and safety and drug approvals.

2:08Appreciation to our sponsor for backing this episode. When you want calm, do not reach for your phone. Lay back and listen, S-O-L-L-I-SoliPillo.com.